Recurrent Clostridium difficile infection is associated with increased mortality

Clinical Microbiology and Infection

Volumn 21, Issue 2, 2015, Pages 164-170

  Olsen, M A ^a   Yan, Y ^a   Reske, K A ^a   Zilberberg, M D ^b,c   Dubberke, E R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EviMed Research Group LLC   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Clostridium difficile; Cohort; Epidemiology; Mortality; Recurrence; Survival

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTACID AGENT; ANTIFUNGAL AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; HYPERTENSIVE FACTOR; LINEZOLID; MACROLIDE; QUINOLONE DERIVATIVE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DEATH; DEMOGRAPHY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY CARE CENTER; VERY ELDERLY; ADOLESCENT; CLOSTRIDIUM INFECTION; DIARRHEA; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; RISK ASSESSMENT; SURVIVAL; UNIVERSITY HOSPITAL; YOUNG ADULT;

CLOSTRIDIUM DIFFICILE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; DIARRHEA; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84923034822     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.08.017     Document Type: Article

References (29)

1. Dubberke E.R., Butler A.M., Reske K.A., Agniel D., Olsen M.A., D'Angelo G., et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008, 14:1031-1038.
2. Honda H., Yamazaki A., Sato Y., Dubberke E.R. Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe 2014, 25:5-10.
3. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. NEngl J Med 2005, 353:2442-2449.
4. Miller M., Gravel D., Mulvey M., Taylor G., Boyd D., Simor A., et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010, 50:194-201.
5. Morrison R.H., Hall N.S., Said M., Rice T., Groff H., Brodine S.K., et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011, 53:1173-1178.
6. Schmid D., Kuo H.W., Simons E., Kanitz E.E., Wenisch J., Allerberger F., et al. All-cause mortality in hospitalized patients with infectious diarrhea: Clostridium difficile versus other enteric pathogens in Austria from 2008 to 2010. JInfect Public Health 2014, 7:133-144.
7. Mlangeni D.A., Harris M.D., Franklin L., Hunt P., Karas J.A., Enoch D.A. Death certificates provide a poor estimation of attributable mortality due to Clostridium difficile when compared to a death review panel using defined criteria. JHosp Infect 2011, 77:370-371.
8. Karas J.A., Enoch D.A., Aliyu S.H. Areview of mortality due to Clostridium difficile infection. JInfect 2010, 61:1-8.
9. Garey K.W., Sethi S., Yadav Y., Dupont H.L. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. JHosp Infect 2008, 70:298-304.
10. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. JInfect 2009, 58:403-410.
11. Pepin J., Routhier S., Gagnon S., Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006, 42:758-764.
12. Taori S.K., Wroe A., Poxton I.R. Clostridium difficile infections in South East Scotland: mortality and recurrence in a region without PCR ribotype 027. JMed Microbiol 2013, 62:1468-1477.
13. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40:373-383.
14. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. JClin Epidemiol 1992, 45:613-619.
15. McDonald L.C., Coignard B., Dubberke E., Song X., Horan T., Kutty P.K. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007, 28:140-145.
16. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
17. Rubin D.B. Multiple Imputation After 18+ Years. JAm Stat Assoc 1996, 91:473-479.
18. Mitchell B.G., Gardner A., Hiller J.E. Mortality and Clostridium difficile infection in an Australian setting. JAdv Nurs 2013, 69:2162-2170.
19. Walter L.C., Brand R.J., Counsell S.R., Palmer R.M., Landefeld C.S., Fortinsky R.H., et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA 2001, 285:2987-2994.
20. Matzen L.E., Jepsen D.B., Ryg J., Masud T. Functional level at admission is a predictor of survival in older patients admitted to an acute geriatric unit. BMC Geriatr 2012, 12:32.
21. Helms M., Vastrup P., Gerner-Smidt P., Molbak K. Excess mortality associated with antimicrobial drug-resistant Salmonella Typhimurium. Emerg Infect Dis 2002, 8:490-495.
22. Helms M., Simonsen J., Molbak K. Quinolone resistance is associated with increased risk of invasive illness or death during infection with Salmonella serotype Typhimurium. JInfect Dis 2004, 190:1652-1654.
23. Helms M., Simonsen J., Olsen K.E., Molbak K. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. JInfect Dis 2005, 191:1050-1055.
24. Petrella L.A., Sambol S.P., Cheknis A., Nagaro K., Kean Y., Sears P.S., et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C.difficile BI strain. Clin Infect Dis 2012, 55:351-357.
25. Walker A.S., Eyre D.W., Wyllie D.H., Dingle K.E., Griffiths D., Shine B., et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013, 56:1589-1600.
26. Cammarota G., Ianiro G., Gasbarrini A. Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review. JClin Gastroenterol 2014, 48:693-702.
27. Cornely O.A., Crook D.W., Esposito R., Poirier A., Somero M.S., Weiss K., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12:281-289.
28. Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEngl J Med 2011, 364:422-431.
29. Ritter A.S., Petri W.A. New developments in chemotherapeutic options for Clostridium difficile colitis. Curr Opin Infect Dis 2013, 26:461-470.